Italfarmaco S.p.A.

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
HDACSmall molecule
Duchenne Muscular DystrophyPolycythemia Vera

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
GivinostatPhase 2Chronic Myeloproliferative Neoplasms
Est. primary completion 2026-12 · NCT01761968 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
GivinostatPhase 3Duchenne Muscular Dystrophy
Est. primary completion 2028-02 · NCT05933057 · CT.gov ↗
What to watch
2029 (2)
December 2029 (2)
GivinostatPhase 2Duchenne Muscular Dystrophy
Est. primary completion 2029-12 · NCT06769633 · CT.gov ↗
What to watch
GivinostatPhase 2/3Duchenne Muscular Dystrophy
Est. primary completion 2029-12 · NCT03373968 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.